Back to Search
Start Over
Concurrent capecitabine and upper abdominal radiation therapy is well tolerated
- Source :
- Radiation Oncology, Vol 1, Iss 1, p 41 (2006)
- Publication Year :
- 2006
- Publisher :
- BMC, 2006.
-
Abstract
- Abstract We retrospectively evaluated acute toxicity in 88 patients that were treated with capecitabine and concurrent radiotherapy to the upper abdomen. These patients included 28 (32%) with pancreatic adenocarcinoma, 18 (20%) with cholangiocarcinoma, 11 (13%) with ampullary carcinoma, 11 (13%) with other primary tumors, 14 (16%) with liver metastases, and 6 (7%) with metastases at other sites. The median dose of radiotherapy was 45 Gy (range 30–72 Gy). The median dose of capecitabine was 850 mg/m2 twice daily, with 77% receiving 800–900 mg/m2 twice daily. The highest grade of acute toxicity was Common Terminology Criteria (CTC) grade 0 in 5 (6%), grade 1 in 60 (68%), grade 2 in 18 (20%), and grade 3 in 5 (6%) patients. No patient had CTC grade 4 toxicity. The most common grade 2 toxicities were nausea, hand-foot syndrome, fatigue, anorexia and diarrhea. The grade 3 toxicities included nausea, vomiting and fatigue. Three patients (3%) required hospitalization due to grade 3 acute toxicity. Capecitabine was interrupted, discontinued or given at an adjusted dose in 13 (15%) patients because of acute toxicity. Therefore, capecitabine and concurrent radiotherapy to the upper abdomen appears to be well tolerated. Capecitabine may serve as an alternative to bolus or infusional 5-FU during chemoradiation for upper gastrointestinal malignancies.
Details
- Language :
- English
- ISSN :
- 1748717X
- Volume :
- 1
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Radiation Oncology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.74b6626639ee47d98b40e11efd5a8de4
- Document Type :
- article
- Full Text :
- https://doi.org/10.1186/1748-717X-1-41